secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001193125-23-088024
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences reports FY 2022 net loss of $13.9M; advancing FB-102 toward clinic in late 2023/early 2024
--------------------------------------------------------------------------------

- Net loss of $13.9M ($0.80/sh) vs $21.7M ($1.55/sh) in FY 2021; cash and equivalents $41.1M at year-end.
- R&D expenses decreased to $5.6M from $13.9M due to termination of FB-401; G&A rose to $8.3M.
- Lead candidate FB-102 for autoimmune diseases expected to enter clinic in late 2023 or early 2024.
- Board appointed David Gryska (former CFO of Incyte and Celgene) in January 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523088024/0001193125-23-088024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523088024/d475905d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-088024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer